Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily

Abstract

We have developed a technology for efficiently enhancing the anticancer apoptosis-inducing activity of agonistic antibodies against the tumor necrosis factor receptor (TNFR) superfamily by the formation of immunoliposomes. To induce apoptosis in cancer cells, agonistic antibodies to the TNFR superfamily normally need cross-linking by internal immune effector cells via the Fc region after binding to receptors on the cell membrane. To develop apoptosis-inducing antibodies that do not require the support of cross-linking by immune cells, we prepared immunoliposomes conjugated with TRA-8, an agonistic antibody against death receptor 5 (DR5), with various densities of antibody on the liposome surface, and evaluated their activities. The TRA-8 immunoliposomes exhibited apoptosis-inducing activity against various DR5-positive human carcinoma cells at a significantly lower concentration without cross-linking than that of the original TRA-8 and its natural ligand (TRAIL). The activity of the immunoliposomes was correlated with the density of antibodies on the surface. As the antibody component, not only the full-length antibody but also the Fab' fragment could be used, and the TRA-8 Fab' immunoliposomes also showed exceedingly high activity compared with the parental antibody, namely, TRA-8. Moreover, cytotoxicity of the TRA-8 full-length or Fab' immunoliposome against normal cells, such as human primary hepatocytes, was lower than that for TRAIL. Enhanced activity was also observed for immunoliposomes conjugated with other apoptosis-inducing antibodies against other receptors of the TNFR superfamily, such as death receptor 4 (DR4) and Fas. Thus, immunoliposomes are promising as a new modality that could exhibit significant activity at a low dose, for cost-effective application of an antibody fragment and with stable efficacy independent of the intratumoral environment of patients as a TNF superfamily agonistic therapy.

Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells

“…Spacer length is an important factor in the efficiency of nanoconjugates. PEG spacers enhanced the efficacy of DMFT systems based on flexible HPMA copolymer molecules [ 28 ] as well as multivalent liposomes [ 36 ]. Since HSA has a relatively rigid structure, introduction of a flexible spacer between HSA and MORF2 should enhance biorecognition and apoptosis induction.…”

A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

“…Antibody fragments can modify a variety of nano-carrier system, such as liposomes, micelles, artificial cells, and nanogels [95,96,97]. Li et al synthesized PH-sensitive immunoliposomes using anti-HER2 Fab fragments to modify PHsensitive liposomes [98].…”

Construction and characterization of immunoliposomes targeting fibroblast growth factor receptor 3

“…Liposome is a single layer or multilayer vesicle composed of lipid bilayer, and can be absorbed by the reticuloendothelial system after intravenous injection, so it is widely used in the transportation of anticancer drugs (Feng et al 2017). Immunoliposomes can recognize specific receptors of tumor cells and deliver drugs or siRNA into the target cells (Ju et al 2014; Niwa et al 2018). Immunoliposomes have been used as targeted carriers for drugs, such as pancreatic ductal adenocarcinoma (Urey et al 2017), breast cancer (Rodallec et al 2018) and skin cancer (Petrilli et al 2018).…”